Popular on eTradeWire
- - 211
- June 14, 2025 The Color Bar Joins "Outrun Hunger" - 205
- "Privacy" & more on PriceofBusiness.com: Latest Guest Posts & Articles for June 13th 202 - 167
- The Matrix Opal by Stella Atrium - A Dystopian Science Fiction Novel - 155
- Introducing GANCloud — The Future of Memory Starts Here - 146
- Nature-Based Printables Help Rhode Island Families Turn Beach Days into Learning Adventures - 136
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence - 127
- "Don't You Dare Give Up On God" (2nd Edition) Offers Unshakable Hope for Christians Struggling with Silence, Suffering, and Spiritual Burnout - 126
- Paulding County GOP Chair Ricky Hess Hosts Flag Waving Event joined by Veterans for America First - 118
- Aerial Survey Equipment Rental Expands: RIEGL VQ-1560 II-S for Rent Now Available Worldwide from AerialSurvey.com - 115
Similar on eTradeWire
- Ben Pouladian, CEO of BEP Holdings, to Join ISPE Los Angeles Biomanufacturing Panel
- Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
- Control Solutions Inc. awarded Biomedical Refrigeration & Freezer agreement with Premier, Inc
- $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
- $750 Million Ketamine Drug Market Withing Reach via New Commissioner's National Priority Vouchers with Anticipated Approval by Year-End for NRx
- Vision Share to Distribute KeraNatural® & halo® in Select Global Markets
- Introducing GANCloud — The Future of Memory Starts Here
ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
eTradeWire News/10807043
PUDONG, China - eTradeWire -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Azstarys (serdexmethylphenidate/dexmethylphenidate extended-release capsules) and granted it Priority Review designation. The investigational therapeutic drug is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged six years and above.
First Methylphenidate Combination Drug Poised to Benefit Patients in China
Azstarys (AK0901) is the first and currently the sole globally approved ADHD combination therapeutic pairing immediate-release dexmethylphenidate (d-MPH) with the prodrug serdexmethylphenidate (SDX). Approved by the U.S. FDA in 2021, Azstarys represents a new generation of methylphenidate medications, providing a dual-phase release profile that offers both rapid onset and sustained symptom control. This novel formulation sets a new benchmark in the management of ADHD for safety, efficacy, and convenience of administering for patients, making it a potential best-in-class ADHD therapeutic drug.
More on eTradeWire News
Pharmacokinetic Property: Biphasic Release for Rapid Onset and Whole-Day Symptom Control
- Rapid onset: Immediate-release d-MPH ensures symptom relief within 30 minutes, offering fast control over core ADHD symptoms.
- Extended control: SDX is metabolized slowly into d-MPH in intestine over time, ensuring up to 13 hours of therapeutic effect with reduced risk of evening rebound symptoms.
- Stable Release Profile: Designed to support the full span of a patient's day—from school or work to evening activities—Azstarys enhances adherence and minimizes sleep disruptions, suiting both pediatric and adult populations.
Abuse-Deterrent Design
Azstarys incorporates an inherent abuse-deterrent design through the inclusion of SDX, which undergoes slow conversion in the gastrointestinal tract. This limits peak plasma concentrations of d-MPH and significantly reduces the potential for misuse via non-oral routes—a key public health consideration in ADHD pharmacotherapy.
Robust Clinical Efficacy and Safety Confirmed in China Phase III Trial
More on eTradeWire News
- In a multicenter Phase III trial spanning eight leading clinical hospitals in China, Azstarys demonstrated statistically significant improvements over placebo in primary and secondary efficacy endpoints.
- The study reported no drug related serious adverse events, affirming Azstarys's favorable safety and tolerability profile, critical for long-term use in pediatric settings.
Transforming ADHD Treatment Paradigm in China
As the third-generation methylphenidate therapy, Azstarys delivers a new standard of care in ADHD management by integrating rapid onset and full-day symptom control into a single dose. Its future approval in China would mark the introduction of the first ADHD combination medication to the market, offering a better option for patients, families, and physicians.
Azstarys® is a registered trademark of Corium in the United States.
For more information about the company, please visit our website: http://www.arkbiosciences.com
Investor Inquiries:IR@arkbiosciences.com
First Methylphenidate Combination Drug Poised to Benefit Patients in China
Azstarys (AK0901) is the first and currently the sole globally approved ADHD combination therapeutic pairing immediate-release dexmethylphenidate (d-MPH) with the prodrug serdexmethylphenidate (SDX). Approved by the U.S. FDA in 2021, Azstarys represents a new generation of methylphenidate medications, providing a dual-phase release profile that offers both rapid onset and sustained symptom control. This novel formulation sets a new benchmark in the management of ADHD for safety, efficacy, and convenience of administering for patients, making it a potential best-in-class ADHD therapeutic drug.
More on eTradeWire News
- The Starlight Bond: A Romantasy Saga - Ignites a New Dawn on Amazon
- Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft
- Revenue Valve Tells Why Visual Storytelling Is the Secret Weapon for Healthcare Nonprofits
- Renowned Businessman, Acy Brown, Intertwines Philanthropy and Public Service in an Impactful Way
- Real-Time Protection Against Costly UCaaS Configuration Errors and Toll Fraud
Pharmacokinetic Property: Biphasic Release for Rapid Onset and Whole-Day Symptom Control
- Rapid onset: Immediate-release d-MPH ensures symptom relief within 30 minutes, offering fast control over core ADHD symptoms.
- Extended control: SDX is metabolized slowly into d-MPH in intestine over time, ensuring up to 13 hours of therapeutic effect with reduced risk of evening rebound symptoms.
- Stable Release Profile: Designed to support the full span of a patient's day—from school or work to evening activities—Azstarys enhances adherence and minimizes sleep disruptions, suiting both pediatric and adult populations.
Abuse-Deterrent Design
Azstarys incorporates an inherent abuse-deterrent design through the inclusion of SDX, which undergoes slow conversion in the gastrointestinal tract. This limits peak plasma concentrations of d-MPH and significantly reduces the potential for misuse via non-oral routes—a key public health consideration in ADHD pharmacotherapy.
Robust Clinical Efficacy and Safety Confirmed in China Phase III Trial
More on eTradeWire News
- Tragic Lyssavirus Death Highlights Importance of Environmental Health Awareness and Bat Safety
- Fully Accountable Introduces Interactive Accounting Scorecard to Improve Financial Performance
- Second Annual Artists' Rights Advocate Award to Be Presented at The Comedy Store on July 17th
- Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
- Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
- In a multicenter Phase III trial spanning eight leading clinical hospitals in China, Azstarys demonstrated statistically significant improvements over placebo in primary and secondary efficacy endpoints.
- The study reported no drug related serious adverse events, affirming Azstarys's favorable safety and tolerability profile, critical for long-term use in pediatric settings.
Transforming ADHD Treatment Paradigm in China
As the third-generation methylphenidate therapy, Azstarys delivers a new standard of care in ADHD management by integrating rapid onset and full-day symptom control into a single dose. Its future approval in China would mark the introduction of the first ADHD combination medication to the market, offering a better option for patients, families, and physicians.
Azstarys® is a registered trademark of Corium in the United States.
For more information about the company, please visit our website: http://www.arkbiosciences.com
Investor Inquiries:IR@arkbiosciences.com
Source: Shanghai Ark Biopharmaceutical Co., Ltd.
Filed Under: Biotech
0 Comments
Latest on eTradeWire News
- Ben Pouladian, CEO of BEP Holdings, to Join ISPE Los Angeles Biomanufacturing Panel
- Chase & Associates Expands Private Equity Recruiting to Help Firms Build High-Performance Teams
- South Shore Food Bank Executive Director Pamela Denholm Honored as a Commonwealth Heroine
- Raksmart: Promoting Security in Global Hosting Service
- Vibrillo Social Launches: A Bold, Privacy-First Alternative to Big Social Media
- ULGSO Hosts The 2025 Urban Champions Youth Summit: "Lead the Way, Don't Be Led Away"
- Elevate Your Organization's Success With Revelescence
- Partners for Breast Cancer Care to host Aug. 14 Free Breast Health Caravan
- $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co
- Hendricks Property Management Earns "Excellent" Verification from PropertyManagement.com
- New Political Thriller X – Revolution by Jason Alexander Challenges Power with Truth
- Sequentex Announces Strategic Partnership with ConnexAI to Accelerate Sales and Outreach for Florida
- CPM Appointed as New Property Management Company for Woodhaven Crossing in Old Bridge, NJ
- Renowned Makeup Artist Dawn Maloney Releases Groundbreaking Book
- Marvelous Mouse Talk Named One of the Top 100 Disney Podcasts by MillionPodcasts
- Local Pub Grows Unique Community Ownership Program
- The Deady Group Joins AVANT's Trusted Advisor™ Network to Expand Technology Enablement Services
- Former Teacher to Dr. Phil's Critique: "Unschooling Isn't Chaos — It's the Future"
- Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
- South Florida Artists Bodhi + Sky, Ages 6 And 9, Head To NYC For Exclusive July Art Exhibition